Search
AC Immune SA
ACIUAdd to Watchlist
2.510USD
+0.130+5.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
255.45MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.46%
5 Days
-1.95%
1 Month
+4.58%
6 Months
-25.30%
Year to Date
-20.06%
1 Year
+21.26%
Key Figures
2.370Open
2.520High
364.87KVolume
LossP/E TTM
9.02P/E Dynamic
--Dividend TTM
0.36%Turnover Ratio
2.380Prev. Close
2.350Low
586.84KTurnover
LossP/E Static
6.33P/B
0.00%Div Yield TTM
-38.00%ROA
4.00052wk High
1.51Volume Ratio
-50.92MNet Profit
101.77MShares
-0.8255EPS TTM
1.61Beta
-104.83%ROE
1.60052wk Low
7.14%Amplitude
100.00%Gross Margin
255.45MMarket Cap
-0.18Reward/Risk
4.58%Risk Rate
TradingKey Stock Score of AC Immune SA
Currency: USD Updated: 2026-07-02Key Insights
AC Immune SA's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 118 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.60.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AC Immune SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
AC Immune SA Highlights
StrengthsRisks
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.52M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.52M.
Overvalued
The company’s latest PE is -3.04, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 26.78M shares, decreasing 5.96% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 389.08 shares of this stock.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
8.600
Target Price
+261.34%
Upside Space
AC Immune SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
AC Immune SA Info
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Ticker SymbolACIU
CompanyAC Immune SA
CEOPfeifer (Andrea)
Websitehttps://www.acimmune.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of AC Immune SA (ACIU)?
The current price of AC Immune SA (ACIU) is 2.51.
What is the symbol of AC Immune SA?
The ticker symbol of AC Immune SA is ACIU.
What is the 52-week high of AC Immune SA?
The 52-week high of AC Immune SA is 4.00.
What is the 52-week low of AC Immune SA?
The 52-week low of AC Immune SA is 1.60.
What is the market capitalization of AC Immune SA?
The market capitalization of AC Immune SA is 255.45M.
Is AC Immune SA (ACIU) currently rated as Buy, Hold, or Sell?
According to analysts, AC Immune SA (ACIU) has an overall rating of STRONG BUY, with a price target of 8.60.
What is the Earnings Per Share (EPS TTM) of AC Immune SA (ACIU)?
The Earnings Per Share (EPS TTM) of AC Immune SA (ACIU) is -0.88.